Grifols, S.A. (GRFS) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
GRFS Revenue Growth
Revenue Breakdown (FY 2025)
GRFS's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
GRFS Revenue Analysis (2014–2025)
As of May 8, 2026, Grifols, S.A. (GRFS) generated trailing twelve-month (TTM) revenue of $7.51 billion, reflecting slight decline in growth of -0.6% year-over-year. The most recent quarter (Q4 2025) recorded $1.96 billion in revenue, up 5.2% sequentially.
Looking at the longer-term picture, GRFS's 5-year compound annual growth rate (CAGR) stands at +6.2%, indicating steady revenue expansion. The company achieved its highest annual revenue of $7.23 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows GRFS's business is primarily driven by Haemoderivatives (86%), Transfusional medicine (8%), and Other Product (3%). With over half of revenue concentrated in Haemoderivatives, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including TAK (-2.0% YoY), CSL (-0.5% YoY), and OCSL, GRFS has underperformed the peer group in terms of revenue growth. Compare GRFS vs TAK →
GRFS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| GRFSCurrent | $7.5B | -0.6% | +6.2% | 16.4% | |
 TAK | $4.58T | -2.0% | +6.8% | 7.5% | |
 CSL | $5.0B | -0.5% | +4.8% | 19.9% | |
 OCSL | $300M | - | - | 50.4% | |
 BCRX | $875M | +75.9% | +117.9% | 39.0% |
GRFS Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $7.23B | +0.2% | $2.58B | 35.7% | $1.19B | 16.4% |
| 2024 | $7.21B | +9.4% | $2.79B | 38.7% | $1.19B | 16.5% |
| 2023 | $6.59B | +8.7% | $2.48B | 37.7% | $782.3M | 11.9% |
| 2022 | $6.06B | +22.9% | $2.21B | 36.5% | $782.4M | 12.9% |
| 2021 | $4.93B | -7.6% | $1.96B | 39.8% | $595.1M | 12.1% |
| 2020 | $5.34B | +4.7% | $2.26B | 42.2% | $996.1M | 18.7% |
| 2019 | $5.10B | +13.6% | $2.34B | 45.9% | $1.13B | 22.2% |
| 2018 | $4.49B | +3.9% | $2.05B | 45.7% | $994.1M | 22.2% |
| 2017 | $4.32B | +6.6% | $2.15B | 49.8% | $1.00B | 23.2% |
| 2016 | $4.05B | +2.9% | $1.91B | 47.2% | $939.4M | 23.2% |
See GRFS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GRFS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare GRFS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonGRFS — Frequently Asked Questions
Quick answers to the most common questions about buying GRFS stock.
Is GRFS's revenue growth accelerating or slowing?
GRFS revenue growth slowed to -0.6%, below the 5-year CAGR of +6.2%. TTM revenue is $7.5B. The deceleration marks a shift from historical growth rates.
What is GRFS's long-term revenue growth rate?
Grifols, S.A.'s 5-year revenue CAGR of +6.2% reflects the variable expansion pattern. Current YoY growth of -0.6% is near this long-term average.
How is GRFS's revenue distributed by segment?
GRFS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.